MX2014013676A - Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia. - Google Patents

Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.

Info

Publication number
MX2014013676A
MX2014013676A MX2014013676A MX2014013676A MX2014013676A MX 2014013676 A MX2014013676 A MX 2014013676A MX 2014013676 A MX2014013676 A MX 2014013676A MX 2014013676 A MX2014013676 A MX 2014013676A MX 2014013676 A MX2014013676 A MX 2014013676A
Authority
MX
Mexico
Prior art keywords
semaphorin
binding molecules
following stroke
promote neurogenesis
neurogenesis following
Prior art date
Application number
MX2014013676A
Other languages
English (en)
Other versions
MX358991B (es
Inventor
Maurice Zauderer
Ernest S Smith
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of MX2014013676A publication Critical patent/MX2014013676A/es
Publication of MX358991B publication Critical patent/MX358991B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente los métodos para promover la neurogénesis en el tejido neural de un paciente que muestra al menos un síntoma de un trastorno del sistema nervioso central, el método comprende administrarle a un sujeto en necesidad de la misma, una cantidad efectiva de una molécula de enlace aislada la cual se enlaza específicamente a la semaforina-4D (SEMA4D).
MX2014013676A 2012-05-11 2013-05-10 Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia. MX358991B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261646119P 2012-05-11 2012-05-11
US13/842,523 US10494440B2 (en) 2012-05-11 2013-03-15 Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
PCT/US2013/040661 WO2013170221A1 (en) 2012-05-11 2013-05-10 Use of semaphorin-4d binding molecules to promote neurogenesis following stroke

Publications (2)

Publication Number Publication Date
MX2014013676A true MX2014013676A (es) 2015-02-05
MX358991B MX358991B (es) 2018-08-31

Family

ID=49548777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013676A MX358991B (es) 2012-05-11 2013-05-10 Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.

Country Status (18)

Country Link
US (1) US10494440B2 (es)
EP (1) EP2846831B1 (es)
JP (1) JP6218810B2 (es)
KR (1) KR102105436B1 (es)
CN (2) CN110064054A (es)
AU (1) AU2013259192B2 (es)
BR (1) BR112014028160B1 (es)
CA (1) CA2872928C (es)
DK (1) DK2846831T3 (es)
EA (1) EA030796B1 (es)
ES (1) ES2882881T3 (es)
IL (1) IL235603B (es)
MX (1) MX358991B (es)
NZ (1) NZ630864A (es)
PT (1) PT2846831T (es)
SG (1) SG11201407416XA (es)
WO (1) WO2013170221A1 (es)
ZA (1) ZA201501674B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG175417A1 (en) 2009-05-08 2011-12-29 Vaccinex Inc Anti-cd100 antibodies and methods for using the same
JP6395606B2 (ja) 2011-10-11 2018-09-26 バクシネックス インコーポレーティッド 血液脳関門透過性の調節のためのセマフォリン−４ｄ結合分子の使用
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
DK3013350T3 (da) 2013-06-25 2020-04-14 Vaccinex Inc Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
WO2017184951A1 (en) 2016-04-22 2017-10-26 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
MX2019001453A (es) 2016-08-02 2019-06-20 Vaccinex Inc Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas.
RU2766341C2 (ru) * 2017-02-22 2022-03-15 Вакцинекс, Инк. Раннее обнаружение активации глиальных клеток при нейродегенеративных или нейровоспалительных заболеваниях
JP7246320B2 (ja) 2017-05-05 2023-03-27 バクシネックス インコーポレーティッド ヒト抗セマフォリン４ｄ抗体

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
SI1325932T1 (es) 1997-04-07 2005-08-31 Genentech Inc
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU6897998A (en) 1997-04-11 1998-11-11 Dendreon Corporation Composition and method for inducing an immune response against tumour-rela ted antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
WO2000028016A1 (en) 1998-11-10 2000-05-18 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
ATE440869T1 (de) 2001-06-20 2009-09-15 Fibron Ltd Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
KR20060006975A (ko) 2003-05-30 2006-01-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
EP2336178A1 (en) 2003-12-11 2011-06-22 Genentech, Inc. Methods and compositions for inhibiting C-Met dimerization and activation
CA2554735A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US20060003452A1 (en) * 2004-07-01 2006-01-05 Virxsys Corporation Vector packaging cell line
CN104804095A (zh) 2004-08-05 2015-07-29 健泰科生物技术公司 人源化抗c-met 拮抗剂
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
JP2008535856A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌の診断、検出および治療におけるｓｅｍａ４ｄ
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
US7919594B2 (en) * 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
PE20091378A1 (es) 2008-01-10 2009-10-14 Genentech Inc Polipeptidos agonistas plexind1
AU2010224094A1 (en) * 2009-03-13 2011-09-22 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
SG175417A1 (en) 2009-05-08 2011-12-29 Vaccinex Inc Anti-cd100 antibodies and methods for using the same
DK2429585T3 (en) 2009-05-15 2018-07-30 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY
NZ604464A (en) 2010-06-14 2014-03-28 Vaccinex Inc Anti-vegf antibodies and uses thereof
ES2640567T3 (es) 2011-05-13 2017-11-03 National University Corporation Tokyo Medical And Dental University Promotor de la osteogénesis
JP6395606B2 (ja) 2011-10-11 2018-09-26 バクシネックス インコーポレーティッド 血液脳関門透過性の調節のためのセマフォリン−４ｄ結合分子の使用
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
DK3013350T3 (da) 2013-06-25 2020-04-14 Vaccinex Inc Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
RU2766341C2 (ru) * 2017-02-22 2022-03-15 Вакцинекс, Инк. Раннее обнаружение активации глиальных клеток при нейродегенеративных или нейровоспалительных заболеваниях

Also Published As

Publication number Publication date
US10494440B2 (en) 2019-12-03
AU2013259192A1 (en) 2014-11-27
US20130302320A1 (en) 2013-11-14
IL235603A0 (en) 2015-01-29
KR20150018555A (ko) 2015-02-23
NZ630864A (en) 2017-03-31
CN110064054A (zh) 2019-07-30
BR112014028160B1 (pt) 2021-01-12
IL235603B (en) 2020-01-30
CA2872928A1 (en) 2013-11-14
JP2015517502A (ja) 2015-06-22
EP2846831A1 (en) 2015-03-18
DK2846831T3 (en) 2021-10-11
SG11201407416XA (en) 2015-03-30
CA2872928C (en) 2021-02-16
AU2013259192B2 (en) 2018-02-22
ZA201501674B (en) 2021-06-30
PT2846831T (pt) 2021-08-19
EA201492067A1 (ru) 2015-05-29
WO2013170221A1 (en) 2013-11-14
MX358991B (es) 2018-08-31
EA030796B1 (ru) 2018-09-28
JP6218810B2 (ja) 2017-10-25
EP2846831A4 (en) 2015-11-18
CN104619341A (zh) 2015-05-13
ES2882881T3 (es) 2021-12-03
EP2846831B1 (en) 2021-07-07
KR102105436B1 (ko) 2020-04-29

Similar Documents

Publication Publication Date Title
MX358991B (es) Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
MX2014004457A (es) Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro.
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
AU2011328009A8 (en) Compounds and methods for treating pain
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
MX2021008755A (es) Un anticuerpo anti-tau para usarse al tratar una tauopatia.
EA201391585A1 (ru) Терапевтические нуклеазные композиции и способы
EA201590783A1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
PH12014502406A1 (en) Anti-il-23p19 antibodies
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2013006056A (es) Metodos para diagnosticar y tratar trastornos relacionados con la longitud del ojo.
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
MX356933B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
WO2012136351A8 (en) Tapentadol for treating pain associated with trigeminal neuralgia
WO2012004416A3 (en) Treatment of a disease associated with retinal degenerative disorder
TN2013000433A1 (en) Therapeutic nuclease compositions and methods
TN2014000207A1 (en) Anti il-36r antibodies
BR112013028891A2 (pt) molécula para tratar um distúrbio inflamatório

Legal Events

Date Code Title Description
FG Grant or registration